TW202321210A - 用於治療冠狀病毒相關疾病之化合物及組成物 - Google Patents

用於治療冠狀病毒相關疾病之化合物及組成物 Download PDF

Info

Publication number
TW202321210A
TW202321210A TW111127023A TW111127023A TW202321210A TW 202321210 A TW202321210 A TW 202321210A TW 111127023 A TW111127023 A TW 111127023A TW 111127023 A TW111127023 A TW 111127023A TW 202321210 A TW202321210 A TW 202321210A
Authority
TW
Taiwan
Prior art keywords
carbonitrile
isoquinolin
oxyimidazoline
substituted
unsubstituted
Prior art date
Application number
TW111127023A
Other languages
English (en)
Chinese (zh)
Inventor
包登輝
郭鋒鋒
馬修 詹姆士 赫塞
維克多 霍爾納克
薩揚 約瑟夫
湯瑪斯 馬丁 二世 奇蘭
劉波
林海耀
苗亞楠
海恩茲 恩斯特 墨瑟
朱利恩 帕皮倫
屈陽
石磊
強 元
張騰
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202321210A publication Critical patent/TW202321210A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111127023A 2021-07-22 2022-07-19 用於治療冠狀病毒相關疾病之化合物及組成物 TW202321210A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163224793P 2021-07-22 2021-07-22
US63/224,793 2021-07-22
US202163289009P 2021-12-13 2021-12-13
US63/289,009 2021-12-13

Publications (1)

Publication Number Publication Date
TW202321210A true TW202321210A (zh) 2023-06-01

Family

ID=82742919

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111127023A TW202321210A (zh) 2021-07-22 2022-07-19 用於治療冠狀病毒相關疾病之化合物及組成物

Country Status (11)

Country Link
US (1) US20250092016A1 (enExample)
EP (1) EP4373814A1 (enExample)
JP (1) JP2024527424A (enExample)
KR (1) KR20240038996A (enExample)
AU (1) AU2022315058A1 (enExample)
CA (1) CA3226758A1 (enExample)
MX (1) MX2024000986A (enExample)
PY (1) PY2261702A (enExample)
TW (1) TW202321210A (enExample)
UY (1) UY39863A (enExample)
WO (1) WO2023002409A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7559223B2 (ja) 2020-08-24 2024-10-01 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物及びその使用
TWI925033B (zh) 2020-10-16 2026-05-11 美商基利科學股份有限公司 磷脂化合物及其用途
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
AU2023249953A1 (en) 2022-04-08 2024-10-24 Shionogi & Co., Ltd. Uracil derivative having viral growth inhibitory activity and pharmaceutical composition containing same
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds
CR20250040A (es) 2022-08-05 2025-03-18 Gilead Sciences Inc Inhibidores de la proteasa principal de sars-cov2
WO2025125695A2 (en) * 2024-12-17 2025-06-19 Medchemica Consultancy Ltd Chemical compoundsid50000167790940 p. doc 2025-05-07 filing no.:19

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1200825B (de) * 1962-01-13 1965-09-16 Hoechst Ag Verfahren zur Herstellung von 3, 5-Dioxo-triazolidinen
PE20121048A1 (es) * 2009-06-26 2012-08-25 Novartis Ag Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17

Also Published As

Publication number Publication date
AU2022315058A1 (en) 2024-02-08
MX2024000986A (es) 2024-02-12
WO2023002409A1 (en) 2023-01-26
UY39863A (es) 2023-02-28
CA3226758A1 (en) 2023-01-26
US20250092016A1 (en) 2025-03-20
EP4373814A1 (en) 2024-05-29
PY2261702A (es) 2023-06-14
KR20240038996A (ko) 2024-03-26
JP2024527424A (ja) 2024-07-24

Similar Documents

Publication Publication Date Title
US20250092016A1 (en) Compounds and compositions for the treatment of coronaviral related diseases
JP6735330B2 (ja) Ｔｒｐａ１調節因子として有用な置換複素環式スルホンアミド化合物
JP7097373B2 (ja) キナーゼ阻害剤としてのアミノトリアゾロピリジン
AU2018221812B2 (en) Pyrrolo [1,2-b] pyridazine derivatives
EP3102572B1 (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP6388991B2 (ja) キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド
TWI594997B (zh) 流感病毒複製之抑制劑
TWI567062B (zh) 新穎吡啶衍生物
WO2023064857A1 (en) Quinoline compounds as inhibitors of kras
JP5959541B2 (ja) Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
RU2674701C2 (ru) Аминопиридазиноновые соединения в качестве ингибиторов протеинкиназы
JP2022516401A (ja) Ｉｒａｋ分解剤およびそれらの使用
TW202500565A (zh) Shp2磷酸酶抑制劑及其使用方法
JP2020011990A (ja) インフルエンザウイルス複製の阻害剤
TW201444821A (zh) 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TWI712598B (zh) 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
TW201211053A (en) Spiro compound and drug for activating adiponectin receptor
WO2022224223A1 (en) Compounds and compositions for the treatment of coronaviral related diseases
CA3234429A1 (en) Ras inhibitors, compositions and methods of use thereof
WO2019189555A1 (ja) 複素環化合物
CN111417635A (zh) 具有抗呼吸道合胞病毒（rsv）活性的吡唑并嘧啶
EP1757602A1 (en) Vla-4 inhibitor
CN119768169A (zh) 取代的稠合二环化合物以及相关的治疗方法
EA050666B1 (ru) Соединения и композиции для лечения заболеваний, связанных с коронавирусной инфекцией
CN117651699A (zh) 用于治疗冠状病毒相关疾病的化合物和组合物